134 related articles for article (PubMed ID: 10290754)
1. P & T Committee interview: strategies to ensure an effective formulary system.
Riff L; Hutchinson R
Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754
[TBL] [Abstract][Full Text] [Related]
2. Development and implementation of a comprehensive, criteria-based drug-use review program.
Todd MW; Keith TD; Foster MT
Am J Hosp Pharm; 1987 Mar; 44(3):529-35. PubMed ID: 3471089
[TBL] [Abstract][Full Text] [Related]
3. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
Summers KH; Szeinbach SL
Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
[TBL] [Abstract][Full Text] [Related]
4. Survey of formulary system policies and procedures.
Rascati KL
Am J Hosp Pharm; 1992 Jan; 49(1):100-3. PubMed ID: 1570847
[TBL] [Abstract][Full Text] [Related]
5. Strategies for deleting popular drugs from a hospital formulary.
Lemay AP; Salzer LB; Visconti JA; Latiolais CJ
Am J Hosp Pharm; 1981 Apr; 38(4):506-10. PubMed ID: 7282675
[TBL] [Abstract][Full Text] [Related]
6. ASHP guidelines on formulary system management.
Am J Hosp Pharm; 1992 Mar; 49(3):648-52. PubMed ID: 1598948
[No Abstract] [Full Text] [Related]
7. Pharmacoeconomic analysis in formulary decisions: an international perspective.
Johnson JA; Bootman JL
Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
[TBL] [Abstract][Full Text] [Related]
8. Improving pharmacy and therapeutics committee operations.
Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
[TBL] [Abstract][Full Text] [Related]
9. Use of criteria developed before formulary addition to evaluate misoprostol use.
Rice KM; LeRoy ML; Ivey MF; Deck C; Krstenansky P
Am J Hosp Pharm; 1992 Mar; 49(3):629-31. PubMed ID: 1598943
[No Abstract] [Full Text] [Related]
10. Reducing the number of formulary theophylline preparations.
Anandan JV
Am J Hosp Pharm; 1981 Apr; 38(4):511-3. PubMed ID: 7282676
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial formulary management: meeting the challenge in a health maintenance organization.
Carlson JA
Pharmacotherapy; 1991; 11(1 ( Pt 2)):32S-35S. PubMed ID: 2011571
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial formulary management: a case study in a teaching hospital.
Wright DB
Pharmacotherapy; 1991; 11(1 ( Pt 2)):27S-31S. PubMed ID: 2011570
[TBL] [Abstract][Full Text] [Related]
13. Key inventory to formulary to cut drug costs.
Schmieding JL; Sita MJ
Hospitals; 1980 Sep; 54(17):78-81. PubMed ID: 7399457
[TBL] [Abstract][Full Text] [Related]
14. Computer-based support system for formulary decisions.
Senthilkumaran K; Shatz SM; Kalies RF
Am J Hosp Pharm; 1987 Jun; 44(6):1362-6. PubMed ID: 3618613
[TBL] [Abstract][Full Text] [Related]
15. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
Hayman JN; Sbravati EC
Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic review performed by a pharmacy and therapeutics subcommittee.
Klapp DL; Ramphal R
QRB Qual Rev Bull; 1982 Jan; 8(1):15-9. PubMed ID: 6803205
[No Abstract] [Full Text] [Related]
17. Antimicrobial cost and quality control: challenges in the 1990s.
Barriere SL
Pharmacotherapy; 1991; 11(1 ( Pt 2)):4S-5S. PubMed ID: 2011572
[TBL] [Abstract][Full Text] [Related]
18. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
Green JA; Chawla AK; Fong PA
Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
[TBL] [Abstract][Full Text] [Related]
19. Chairman of the Joint Formulary Committee, British National Formulary.
Kendall M
Clin Med (Lond); 2009 Aug; 9(4):349-52. PubMed ID: 19728509
[No Abstract] [Full Text] [Related]
20. Antibiotic review: the experience of one pharmacy and therapeutics committee.
Kiepert DR
QRB Qual Rev Bull; 1979 Jan; 5(1):24-7. PubMed ID: 121376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
